Navigation Links
Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
Date:10/24/2008

PARIS, October 24 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its pipeline will be the subject of five posters at the joint annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (48th annual ICAAC/IDSA 46th annual meeting), which takes place in Washington, DC, October 25-28, 2008.

NXL104, Novexel's broad spectrum class A and C ss-lactamase inhibitor, will be the subject of three posters. In vitro data will be presented showing that a ceftazidime/NXL104 combination is rapidly bactericidal against a range of beta-lactamase-producing Enterobacteriaceae and that one of the most important factors affecting the pharmacodynamics of the combination is maintaining a critical concentration of the inhibitor (NXL104) that suppresses beta-lactamase activity. (Poster A-023). A second poster describes the use of a ceftazidime/NXL104 disk diffusion assay for the detection and identification of the Klebsiella pneumoniae carbapenemase enzyme (KPC) in Enterobacteriaceae (Poster D-291b). The third poster details a microbroth dilution quality control study on ceftazidime/NXL104 (Poster F-2665).

The potent in vitro activity of NXL103, a novel oral streptogramin, will be presented against a range of staphylococci, including vancomycin intermediate and resistant isolates (Poster F1-365).

A fifth poster covers the anti-staphylococcal activity of NXL101, a bacterial gyrase inhibitor, now discontinued.

All posters will be available for download from Novexel's web site (http://www.novexel.com) shortly after the close of ICAAC.

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics de
'/>"/>

SOURCE Novexel
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
2. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
3. Nerviano Medical Sciences Invited by EORTC-NCI-AACR to Present the State-of-the-Art of Aurora
4. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
5. Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting
6. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
7. Cytopia Scientific Presentations on JAK2 Inhibitor Program
8. Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
10. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
11. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: ... Daniel Teper , will present live at VirtualInvestorConferences.com on ... TIME:   11:30AM EDT LINK:    http://tinyurl.com/aug6-pre-imnp ... event where investors are invited to ask the company ... as well as the association,s "virtual trade booth." If ...
(Date:8/3/2015)... Shire plc (LSE: SHP, ... has acquired New York -based, ... With the acquisition, Shire acquires the global rights ... iodine (PVP-I) and 0.1% dexamethasone), a therapy in ... an ocular surface condition commonly referred to as ...
(Date:8/2/2015)... 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... 3 clinical trial met its primary endpoint, showing ... cancer patients with carcinoid syndrome that is not ... Telotristat etiprate was discovered using Lexicon,s gene science, ... company,s first discovery to complete a pivotal Phase ...
Breaking Medicine Technology:Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6
... NEW ORLEANS, June 6 Eli Lilly and Company (NYSE: ... study results of LY2189265, its investigational glucagon-like peptide 1 (GLP-1) ... diabetes. These data will be presented as part of the ... , , In the Phase II study, ...
... American Diabetes Association,s 69th Scientific Sessions shows investigational ... function tests , , NEW ORLEANS, June ... Powder is a well-tolerated, ultra rapid acting insulin ... usual antidiabetic treatment, according to data presented today ...
Cached Medicine Technology:Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes 2Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes 3Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes 4AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA 2AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA 3
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... The art ... experience. Learning from her grandmother’s side at a young age, Nasreen Zereshki was extremely ... has decided to share her cookbook Recipes from My Persian Kitchen with the world. ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... National Forest, to Ahjumawi Lava Springs, California’s northernmost and among its least visited ... untapped ground water aquifers, whose main outflow is at Ahjumawi Lava Springs, part ...
(Date:8/3/2015)... ... ... From 2006-2017 the number of dental laboratories in the ... for the National Association of Dental Laboratories ( NADL ) by Valmont Research ... As the number of dental laboratories decreases, dentists will have fewer options when ...
(Date:8/3/2015)... ... , ... Constantin Vasilica, 48 from Romania wanted to have an alternative healing ... years of suffering and using medications with strong side effects. This had already forced ... time off or wait longer hours in the waiting rooms. Instead, he went home ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Code Council (ICC) announce an agreement to collaborate across a wide range ... to increasing building code knowledge among architects. , “Our combined membership, consisting of ...
Breaking Medicine News(10 mins):Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3
... suicidal thoughts as well, study finds , TUESDAY, June 9 ... bed at 10 p.m. are less apt to become depressed ... much later, recent research shows. , "This study bolsters the ... study author James Gangwisch, an assistant professor of psychiatry at ...
... LANCASTER, Pa., June 9 Herley Industries, Inc. (Nasdaq: ... Lancaster division received a contract award valued at approximately ... manufacture complex Integrated Microwave Assemblies (IMA) for an electronic ... Herley Chairman and CEO, Myron Levy, said, "Herley has ...
... professional pilots for example, depend on good vision as ... not required to undergo regular vision testing. A new ... they don,t recall ever having their vision tested or ... last vision exam. The study, performed at ...
... This release is available in French . ... antifungals are seeping into the waterways of North America, ... in the peer-reviewed journal Environmental Health Perspectives ... researchers, the review found that consumption of anti-infectives for ...
... unions, and veteran political leaders announces support for ... improve outcomes and reduce health care costs for ... support bipartisan reform agreement in Congress , ... an organization bringing together an expanding alliance of ...
... First Sugar-Free Functional Beverage Made Specifically for Kids, Over Soda ... WAT-AAH!, the first sugar-free functional beverage brand made specifically for ... their first nationwide WAT-AAH! Challenge to defy the expectation that ... over water. , , During the months of ...
Cached Medicine News:Health News:Early Bedtime May Help Stave Off Teen Depression 2Health News:Early Bedtime May Help Stave Off Teen Depression 3Health News:Herley Receives a $1.2 Million Contract Award for Complex Integrated Microwave Assemblies for U.S. Electronic Attack Aircraft 2Health News:Antibiotics, antimicrobials and antifungals in waterways 2Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 2Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 3Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 4Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 5Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 6Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 7Health News:Let Water Be Water, LLC Announces Results of the 'WAT-AAH! Challenge' 2
The technology in the LATITUDE system allows your doctor to get the same data from your device whether you are at home or in your doctor's office. This information transfer happens automatically....
Indicated to facilitate the intra-luminal placement of conventional guidewires beyond stenotic lesions, including chronic total coronary occlusions....
... Para 12 is a three-part differential control assayed ... STKR, J Series, T Series, AcT/AcT diff/AcT diff2, ... 1500, 1600, 1700, and 1800; Danam Datacell18, Datacell ... I-1800, I-1800MS/MS PLUS and I-1600; the ABX Micros ...
... Para 5X is a whole blood ... Pentra 60C+, 80 and 120, and the ... product offers a unique white cell differential, ... the algorithms on the systems. The product ...
Medicine Products: